Gjefsen E, Gervin K, Bråten L C H, Goll G L, Aass H C D, Schistad E I, Wigemyr M, Pedersen L M, Skouen J S, Vigeland M D, Selmer K K, Storheim K, Zwart J A
Research and Communication Unit for Musculoskeletal Health (FORMI), Oslo University Hospital HF, Ulleval, Bygg 37b, P.O. Box 4956 Nydalen, 0424 Oslo, Norway; Faculty of Medicine, University of Oslo, Norway.
Department of Research and Innovation, Division of Clinical Neuroscience, Oslo University Hospital, Norway.
Osteoarthritis Cartilage. 2023 Apr;31(4):543-547. doi: 10.1016/j.joca.2023.01.001. Epub 2023 Jan 12.
To explore serum cytokine levels over time in patients with chronic low back pain (cLBP) and Modic changes (MCs), difference in change between treatment groups in the Antibiotics in Modic Changes (AIM) study and associations between change in cytokines and low back pain.
Serum concentrations of 39 cytokines were measured at baseline and 1 year from 73 participants in the AIM study; 30 randomized to placebo, 43 to Amoxicillin. Low back pain intensity was measured by numeric rating scale. Change in cytokine levels over time were assessed by paired t-tests. Difference in change in cytokine levels between treatment groups and associations between changes in LBP and cytokine levels were assessed by linear regression models. Networks of cytokine changes in each treatment groups were explored by Pearson's correlations.
Five cytokines changed from baseline to 1 year, (mean change, log transformed values with CI) C-X-C motif chemokine ligand (CXCL) 10 (IP-10) (0.11 (0.01-0.20)), CXCL13 (0.61 (0.00-0.12)), C-C motif chemokine ligand (CCL)26 (0.05 (0.01-0.1)), granulocyte macrophage-colony stimulating factor (GM-CSF) (-0.12 (-0.23 to 0.00)) and CXCL11 (0.12 (0.03-0.22)). Treatment group only influenced change in CCL21 (β 0.07 (0.01-0.12)), and IL-6 (β -0.17 (-0.30 to -0.03)). Change in CXCL13 (β 2.43 (0.49-4.38)), CCL27 (β 3.07 (0.46-5.69)), IL-8 (β 1.83 (0.08-3.58)) and CCL19 (β 3.10 (0.86-5.43)) were associated with change in LBP. The correlation networks of cytokine changes demonstrate small differences between treatment groups.
Cytokine levels are relatively stable over time in our sample, with little difference between treatment groups. Some cytokines may be associated with LBP intensity. The differences between the correlation networks suggest that long-term Amoxicillin-treatment may have longstanding effects to be further explored.
探讨慢性下腰痛（cLBP）合并Modic改变（MCs）患者血清细胞因子水平随时间的变化、Modic改变中的抗生素（AIM）研究中各治疗组间变化的差异以及细胞因子变化与下腰痛之间的关联。
在AIM研究中，对73名参与者在基线和1年后测量了39种细胞因子的血清浓度；30人随机分配至安慰剂组，43人分配至阿莫西林组。采用数字评分量表测量下腰痛强度。通过配对t检验评估细胞因子水平随时间的变化。通过线性回归模型评估治疗组间细胞因子水平变化的差异以及下腰痛变化与细胞因子水平之间的关联。通过Pearson相关性分析探索各治疗组中细胞因子变化的网络。
从基线到1年，有5种细胞因子发生了变化，（平均变化，经对数转换的值及置信区间）C-X-C基序趋化因子配体（CXCL）10（IP-10）（0.11（0.01-0.20））、CXCL13（0.61（0.00-0.12））、C-C基序趋化因子配体（CCL）26（0.05（0.01-0.1））、粒细胞巨噬细胞集落刺激因子（GM-CSF）（-0.12（-0.23至0.00））和CXCL11（0.12（0.03-0.22））。治疗组仅影响CCL21（β 0.07（0.01-0.12））和IL-6（β -0.17（-0.30至-0.03））的变化。CXCL13（β 2.43（0.49-4.38））、CCL27（β 3.07（0.46-5.69））、IL-8（β 1.83（0.08-3.58））和CCL19（β 3.10（0.86-5.43））的变化与下腰痛的变化相关。细胞因子变化的相关网络显示治疗组间存在微小差异。
在我们的样本中，细胞因子水平随时间相对稳定，治疗组间差异不大。一些细胞因子可能与下腰痛强度相关。相关网络之间的差异表明，长期阿莫西林治疗可能具有有待进一步探索的长期影响。
